References
- Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol 2010;28:197–201
- Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010;36:1–53
- Vazquez JA. Invasive fungal infections in the intensive care unit. Semin Respir Crit Care Med 2010;31:79–86
- Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001;33:690–9
- Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327–60
- Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007;27:369–88
- Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008;61:i41–4
- Oberoi JK, Wattal C, Goel N, et al. Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res 2013;136:997–1003
- Santoni G, Spreghini E, Lucciarini R, et al. Involvement of alpha(v)beta3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line. Microb Pathog 2001;31:159–72
- Spreghini E, Gismondi A, Piccoli M, Santoni G. Evidence for alphavbeta3 and alphavbeta5 integrin-like vitronectin (VN) receptors in Candida albicans and their involvement in yeast cell adhesion to VN. J Infect Dis 1999;180:156–66
- Leng Q, Mixson AJ. Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection. Nucleic Acids Res 2005;33:e40
- Zhu J, Luther PW, Leng Q, Mixson AJ. Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrob Agents Chemother 2006;50:2797–805
- Verwer PE, Woodle MC, Boekhout T, et al. Cryptococcus and Trichosporon spp. are susceptible in vitro to branched histidine- and lysine-rich peptides (BHKPs). J Antimicrob Chemother 2011;66:1649–52
- Edgerton M, Koshlukova SE, Lo TE, et al. Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J Biol Chem 1998;273:20438–47
- Kavanagh K, Dowd S. Histatins: antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 2004;56:285–9
- Mochon AB, Liu H. The antimicrobial peptide histatin-5 causes a spatially restricted disruption on the Candida albicans surface, allowing rapid entry of the peptide into the cytoplasm. PLoS Pathog 2008;4:e1000190
- Matejuk A, Leng Q, Begum MD, et al. Peptide-based antifungal therapies against emerging infections. Drugs Future 2010;35:197–210
- Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149
- Makarem R, Newham P, Askari JA, et al. Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin alpha 4 beta 1. J Biol Chem 1994;269:4005–11
- Chou ST, Leng Q, Scaria P, et al. Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition. Biomacromolecules 2013;14:752–60
- Lionakis MS, Lahdenranta J, Sun J, et al. Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. Infect Immun 2005;73:7747–58